Finance

Lists
TRGNF:OTCMKTS
Transgene SA
$0.80
0.00%
(0.00) 1D
Aug 14, 1:41:16 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRGNF...
Mkt. cap
278.22M
Avg. vol.
3.00
Volume
0.00
52-wk high
$1.08
52-wk low
$0.80
Shares outstanding
278.56M
No. of employees
145
Mkt. cap
278.22M
Avg. vol.
3.00
Volume
0.00
52-wk high
$1.08
52-wk low
$0.80
Shares outstanding
278.56M
No. of employees
145
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells. Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses. Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer. The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA
CEO-
Employees145
FoundedDec 1979
Headquarters-
SectorBiotechnology
Websitetransgene.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
2.29M
2.29M
1.32M
1.32M
Cost of goods sold
8.96M
8.96M
7.99M
7.99M
Cost of revenue
8.96M
8.96M
7.99M
7.99M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.89M
1.89M
1.76M
1.76M
Operating expense
1.86M
1.86M
2.32M
2.32M
Total operating expenses
10.82M
10.82M
10.32M
10.32M
Operating income
-8.53M
-8.53M
-9.00M
-9.00M
Other non operating income
-69.50K
-69.50K
-121.50K
-121.50K
EBT including unusual items
-9.65M
-9.65M
-9.11M
-9.11M
EBT excluding unusual items
-9.65M
-9.65M
-9.11M
-9.11M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-27.00K
-27.00K
558.00K
558.00K
Net income
-9.65M
-9.65M
-9.11M
-9.11M
Net profit margin
-421.38%
-421.38%
-692.85%
-692.85%
Earnings per share
-
-
-
-
Interest and investment income
111.50K
111.50K
174.00K
174.00K
Interest expense
-460.00K
-460.00K
-194.50K
-194.50K
Net interest expenses
-348.50K
-348.50K
-20.50K
-20.50K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.20M
-8.20M
-8.66M
-8.66M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps